Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Stopped Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.
Conditions
- NSCLC (Non-small Cell Lung Carcinoma)
Interventions
- DRUG: Itacitinib
- DRUG: docetaxel
Sponsor
Incyte Corporation